Cardiovascular Systems gets nod for new heart device
(Reuters) - Cardiovascular Systems Inc received U.S. Food and Drug Administration approval to start selling its heart device to treat severe calcium deposits in coronary arteries, sending its shares up as much as 23 percent.
The device, Diamondback 360 Coronary Orbital Atherectomy System, will be launched immediately after the FDA's marketing approval, the company said on Tuesday.
Plaque build up, including calcium deposits, in arteries reduces blood supply to the heart, leading to coronary artery disease.
The company estimated the U.S. market opportunity for the device to exceed $1.5 billion annually.
Wunderlich Securities analyst James Terwilliger raised his price target on the company's stock to $30 from $24.
Cardiovascular shares touched a near six-year high of $27.90 in early trading on the Nasdaq, but eased back to $26.86.
(Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila, Maju Samuel)
- Gaza fighting abates as diplomatic tension flares |
- Hague court orders Russia to pay $50 billion in Yukos case
- Pushing locals aside, Russians take top rebel posts in east Ukraine
- Europe subdued, Russia shares tumble on new sanctions
- Fighting complicates Ukraine crash probe, U.S., EU prepare Russia sanctions |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video